Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
03 Apr 2019
Long-term treatment with glucocorticoids (GC) is necessary in polymyalgia rheumatica (PMR), but preliminary data of a study suggests that use of amino bisphosphonates (N-BP) correlates with GC discontinuation in the management of PMR.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.

Glecaprevir–pibrentasvir regimen effective against genotype 2 HCV in haemodialysis patients

29 Jul 2019

An 8- or 12-week regimen of glecaprevir plus pibrentasvir (G/P) appears to be safe and effective in the treatment of genotype 2 hepatitis C virus (HCV) infection in patients undergoing haemodialysis, as reported in a recent Japanese cohort study.

Researchers followed a total of 27 patients who initiated G/P regimen. Thirteen nonliver cirrhosis (LC) and direct-acting antivirals (DAAs)-naïve patients received the 8-week regimen, while 14 patients with LC (n=13) or history of DAA failure (n=1) received the 12-week regimen.

All but one patient (96.3 percent) achieved sustained virological response at 12 weeks following treatment completion (SVR12). There were two cases of treatment withdrawal: one was at week 11 due to cerebral infarction (which was resolved by conservative management) and the other was at week 2 due to exacerbation of pruritis. The patient who discontinued G/P at week 2 belonged to the 12-week regimen arm and could not achieve SVR12.

Adverse events occurred in 51.9 percent (14/27) of the population, with the most common being pruritus (29.6 percent; 8/27). None of the patients experienced lethal adverse events.

Glecaprevir is a novel HCV NS5A inhibitor, while pibrentasvir is an HCV protease inhibitor. Notably, these drugs could initially reduce the treatment duration for HCV-infected patients without liver cirrhosis. The efficacy of the G/P regimen has also been demonstrated in a previous trial involving patients with severe renal dysfunction, but the treatment duration was standardized to 12 weeks.  [J Gastroenterol 2018;53:557-565; Hepatology 2018;68:1298-1307; N Engl J Med 2017;377:1448-1555]

Therefore, the present data show that a shorter treatment duration with G/P, similar to that of patients without severe renal dysfunction, is highly effective for haemodialysis patients with genotype 2 HCV infection, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
03 Apr 2019
Long-term treatment with glucocorticoids (GC) is necessary in polymyalgia rheumatica (PMR), but preliminary data of a study suggests that use of amino bisphosphonates (N-BP) correlates with GC discontinuation in the management of PMR.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.